PubMed Health⌕ Search

Biomedical subjects

G F Hebenstreit

Publications and source records attributed to G F Hebenstreit.

11 recordsLinked to original sources
PubMed1991

A double-blind comparative multicentre study of controlled-release remoxipride, immediate-release remoxipride and haloperidol in schizophrenia.

A double-blind multicentre study comparing the efficacy and safety of remoxipride in controlled-release formulation (REM-CR), given once a day, and immediate-release formulation (REM-IR) and haloperidol, given twice daily, was conducted in patients with schizophrenic illness. In total, 150 inpatients were randomized: 49, 51 and 50 in the REM-CR, REM-IR, and haloperidol groups, respectively. The mean daily dose of REM-CR during the last week of treatment was 361 mg, that of REM-IR 332 mg. In the haloperidol group the corresponding dose was 12.5mg per day. The study treatment period was four weeks. The median BPRS total score was 37.5 in the REM-CR group at start of treatment, and 14.5 at last rating (n = 38). For the REM-IR group and the haloperidol group the corresponding figures were 36.0 and 38.0 at start of treatment and 18.0 (n = 43) and 16.5 (n = 40) at last rating. No statistically significant differences were found between the treatments. Therapy-emergent extrapyramidal symptoms (Simpson & Angus rating scale) were significantly (p less than 0.05) more frequent and more severe during haloperidol than during REM-CR and REM-IR treatment, despite significantly higher concurrent use of anticholinergic drugs in the haloperidol group.--REM-CR was comparable in efficacy and tolerability to REM-IR. The tolerability profile favoured both remoxipride formulations over haloperidol. Evaluation of the clinical chemistry, haematology, and cardiovascular data showed no clinically significant deleterious effects on any organ system for either drug.

Adolescent↗
PubMed1990

Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind multicenter study, Austria.

In a double-blind, 4-week, prospective, randomized multicenter (17 centers) study we checked on the efficacy, tolerability and safety of moclobemide (300-600 mg/d) compared to imipramine (100-200 mg/d) in parallel groups of patients with a Major Depressive Episode (DSM III). The mean % reduction of the HAMD at the end of treatment was 51.7 in the moclobemide group and 52.1 in the imipramine group. The percentage of patients in whom efficacy was globally judged as "good" or "very good" was 62% in the moclobemide group and 60% in the imipramine group. There was no statistically significant difference in the efficacy in both groups but in some factors there was a trend for a better amelioration favoring moclobemide. The final overall physician's judgement of tolerability was "good" or "very good" in 83% of moclobemide patients and in 74% of imipramine patients. Adverse events were reported or observed in 56% of moclobemide patients and in 69% of imipramine patients. The number of mild, moderate and severe adverse events was higher in the imipramine group with a total of 286 versus 189. There was a statistically high significant difference considering the tolerability favoring moclobemide again. In this project the basic goal to find a substance with at least the same efficacy but a much better tolerability for sure got fulfilled.

Adolescent↗
PubMed1989

[3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients.

[3H]MK-801 binding was used as a marker for the NMDA receptorion channel complex in postmortem brain samples from the frontal cortex, hippocampus, putamen, entorhinal region, and amygdala of schizophrenic patients and controls. In schizophrenia [3H]MK-801 binding levels were increased in all brain regions investigated reaching significance in the putamen.

Aged↗
PubMed1989

Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine.

Rolipram improves signal transmission in central noradrenergic neurones at a pre- and postsynaptic level, and is thus a novel approach in antidepressant therapy. In order to prove efficacy, tolerance, and safety, several controlled studies are underway. Results of a randomized double-blind comparative trial versus imipramine involving 64 in-patients with Major Depressive Disorder (DSM III) in six independent centers will be presented and discussed. The chosen biometric model provided evidence that towards the end of the study imipramine was superior to Rolipram. The particular clinical relevance of this difference is discussed. As regards tolerance, nausea emerged as the typical side-effect of Rolipram, whereas imipramine precipitated mainly anticholinergic side-effects.

Adult↗
PubMed1989

[L-tryptophan in pre-delirium and delirium conditions].

The effect of the serotonin precursor l-tryptophan on delirium and pre-delirium states was studied in a prospective study on 32 patients. Patients were given 3 infusions each containing 2.5 g l-tryptophan, a day for at least 7 days. The status of the patients was examined with the Mini Mental State Examination, the SCAG (Sandoz Clinical Assessment Geriatric Scale) and a sleep/awake observation sheet. These showed that the patients experienced significant trends toward improvement. Relevant side effects and interactions were not observed. The application of supplemental tranquilizers could be reduced and in 5 cases it was not necessary at all. It was only necessary to apply l-tryptophan for longer than 7 days in 4 of 32 patients. Furthermore, under this medication no patient in a state of predelirium at delivery into the hospital developed full delirium tremens.

Alcohol Withdrawal Delirium↗
PubMed1987

[Neurologic and psychiatric diseases and fitness for driving].

Out of all neurological and psychiatric diseases from the international point of view alcoholism is the biggest problem in road-traffic. Psychomotor-ability and self-criticism are already impaired at very low doses of alcohol. Driving-ability almost always is reduced in the acute stage of endogenous psychoses, but improves parallel to the improvement of the psychosis. This happens in spite and sometimes even because of psychopharmacotherapy. Almost all patients are able to fulfill the driving-ability requirements after the acute state. Neurological patients are causing less problems in road-traffic than the average population. In epilepsy a small "risk group" could be objectified. This group has a bad compliance and inclines to alcoholism. In the Western part of Lower Austria we have made arrangements concerning standardized requirements for our patients in 1976. This way from the psycho-hygienic point of view we really were very successful. It also should be mentioned that concerning epilepsy we were more or less pursuing the same ideas since 1976 which got recommended by "Epilepsy International" in 1981.

Accidents, Traffic↗
PubMed1986

[Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics].

The influence of celiprolol on the symptoms of tardive dyskinesia was compared with placebo in a randomized double blind study. 17 female patients were treated with a single daily dose of 200 mg celiprolol and 18 female patients received placebo for a period of 3 months. All patients got additional neuroleptic treatment. Celiprolol produced a small decrease in heart rate and systolic blood pressure, but had no influence on the diastolic blood pressure. The effects of celiprolol on the symptoms of tardive dyskinesia were similar to those of the placebo; in both groups improvements and deteriorations were observed. One patient of the celiprolol group became symptom free. Two cases of collapse occurred after 10 weeks of treatment with celiprolol. In one case collapse was associated with diarrhoea, in the other case the patient had preexisting hypotensive circulatory dysregulation. Sporadic reports about the effect of propranolol in patients with tardive dyskinesia might reflect the normal progress of the disease or the effect might depend on the different pharmacological profile of propranolol.

Adult↗